# Hoffmann-La Roche clinical trials: 2,102 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,102 trials with Hoffmann-La Roche as lead sponsor, 89 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Hoffmann-La Roche: 2,102 rows for $101.02, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,102
- Recruiting or not yet: 89
- Read on: November 19, 2026

## Trials

The 25 newest of 2,102, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07937852 | A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS) | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Multiple Sclerosis | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937852) |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| October 30, 2026 | NCT07905924 | A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in... | Hoffmann-La Roche | Phase 1 | Not yet recruiting | Solid Tumors | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905924) |
| October 22, 2026 | NCT07889648 | A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar... | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Type 2 Diabetes Mellitus | 948 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889648) |
| October 20, 2026 | NCT07883577 | A Study of RO7821657 in Participants With Solid Tumors | Hoffmann-La Roche | Phase 1 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883577) |
| September 29, 2026 | NCT07846683 | A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely... | Hoffmann-La Roche | Phase 3 | Recruiting | Moderately to Severely Active Ulcerative Colitis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846683) |
| September 28, 2026 | NCT07843498 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight | 3,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843498) |
| September 28, 2026 | NCT07843485 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843485) |
| September 28, 2026 | NCT07843472 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established... | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Cardiovascular Disease | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843472) |
| September 24, 2026 | NCT07838194 | Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children | Hoffmann-La Roche | Phase 3 | Recruiting | Hemophilia A | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838194) |
| September 22, 2026 | NCT07835243 | A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy Participants | Hoffmann-La Roche | Phase 1 | Not yet recruiting | Healthy Volunteers | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835243) |
| September 18, 2026 | NCT07827599 | A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in... | Hoffmann-La Roche | Phase 3 | Recruiting | Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827599) |
| September 18, 2026 | NCT07827586 | Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis | Hoffmann-La Roche | Observational | Recruiting | Relapsing-Remitting Multiple Sclerosis | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827586) |
| September 18, 2026 | NCT07827573 | A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on... | Hoffmann-La Roche | Phase 3 | Recruiting | Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827573) |
| September 17, 2026 | NCT07825064 | Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously... | Hoffmann-La Roche | Phase 2 | Recruiting | Multiple Myeloma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825064) |
| September 16, 2026 | NCT07822334 | A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | Hoffmann-La Roche | Phase 1/2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822334) |
| August 24, 2026 | NCT07781657 | Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease | Hoffmann-La Roche | Phase 2 | Recruiting | Alzheimer's Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781657) |
| August 24, 2026 | NCT07781644 | Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease | Hoffmann-La Roche | Phase 2 | Recruiting | Parkinson's Disease | 474 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781644) |
| August 6, 2026 | NCT07749157 | A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis | Hoffmann-La Roche | Phase 1 | Not yet recruiting | Relapsing Multiple Sclerosis | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749157) |
| August 5, 2026 | NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC)... | Hoffmann-La Roche | Phase 2 | Recruiting | Breast Cancer, Diabetes Type II | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748208) |
| August 3, 2026 | NCT07741604 | A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions | Hoffmann-La Roche | Phase 1 | Recruiting | Renal Impairment | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741604) |
| July 21, 2026 | NCT07717411 | A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Hoffmann-La Roche | Phase 3 | Recruiting | Alzheimer's Disease | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717411) |
| June 26, 2026 | NCT07670416 | A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670416) |
| June 25, 2026 | NCT07667322 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation... | Hoffmann-La Roche | Phase 1 | Active not recruiting | Multiple Sclerosis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667322) |
| June 24, 2026 | NCT07665723 | An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450... | Hoffmann-La Roche | Phase 1 | Recruiting | Active Ulcerative Colitis | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665723) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 429 |
| Phase 1/2 | 67 |
| Phase 2 | 406 |
| Phase 2/3 | 11 |
| Phase 3 | 570 |
| Phase 4 | 208 |
| Not applicable | 48 |
| Observational | 362 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,648 |
| Terminated | 203 |
| Active not recruiting | 112 |
| Recruiting | 81 |
| Withdrawn | 42 |
| Not yet recruiting | 8 |
| No longer available | 4 |
| Unknown | 3 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 185 |
| Breast Neoplasms | 174 |
| Anemia | 96 |
| Carcinoma, Non-Small-Cell Lung | 90 |
| Colorectal Neoplasms | 83 |
| Hepatitis C, Chronic | 82 |
| Diabetes Mellitus, Type 2 | 68 |
| HIV Infections | 62 |
| Neoplasms | 60 |
| Hepatitis B, Chronic | 45 |
| Melanoma | 45 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 36 |
| Lymphoma, Non-Hodgkin | 35 |
| Alzheimer Disease | 27 |
| Stomach Neoplasms | 25 |
| Acquired Immunodeficiency Syndrome | 25 |
| Lymphoma, Large B-Cell, Diffuse | 24 |
| Osteoporosis, Postmenopausal | 21 |
| Multiple Sclerosis | 21 |
| Ovarian Neoplasms | 20 |
| Influenza, Human | 20 |
| Cytomegalovirus Infections | 19 |
| Schizophrenia | 18 |
| Lymphoma, Follicular | 18 |
| Hemophilia A | 17 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Health food restaurants in the United States](https://specstream.ai/data/businesses/health-food-restaurants/united-states)
- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
- [Farming services in the United States](https://specstream.ai/data/businesses/farming-services/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
